This non-amidated recombinant toxin slows fast inactivation on Nav1.1/SCN1A (EC(50)=52.8 nM), Nav1.4/SN4A (EC(50)=32 nM), Nav1.5/SCN5A (EC(50)=116.7 nM), Nav1.6/SCN8A (EC(50)=46.3 nM), and Nav1.7/SCN9A (EC(50)=147.4 nM) voltage-gated sodium channels (PubMed:32259093). On Nav1.1/SCN1A channel, acts as an agonist by inducing a shift in both the voltage dependence of channel inactivation (alpha-toxin activity) and activation (beta-toxin activity) (PubMed:32259093). Expressed by the venom gland. Has the structural arrangement of an alpha-helix connected to antiparallel beta-sheets by disulfide bonds (CS-alpha/beta). Monoisotopic mass. Lead molecule for the development of selective Nav1.1/SCN1A agonists for the treatment of Dravet syndrome epilepsy. Does not show effects on Nav1.2/SCN2A, and Nav1.3/SCN3A voltage-gated sodium channels (PubMed:32259093). Does not show insecticidal activity (PubMed:32259093). The complete amino acid sequence was obtained by combining proteomic and transcriptomic techniques. Belongs to the long (4 C-C) scorpion toxin superfamily. Sodium channel inhibitor family. Alpha subfamily.